Aslan Pharmaceuticals Ltd
Change company Symbol lookup
Select an option...
ASLN Aslan Pharmaceuticals Ltd
WYND Wyndham Destinations Inc
GRWWF Great Wall Pan Asia Holdings Ltd
BAC Bank of America Corp
FULC Fulcrum Therapeutics Inc
T AT&T Inc
F Ford Motor Co
JNJ Johnson & Johnson
HHER Her Imports
WSBF Waterstone Financial Inc

Health Care : Biotechnology | Small Cap Value
Based in Singapore
Company profile

ASLAN Pharmaceuticals Limited is a clinical-stage oncology and immunology focused biopharmaceutical company. The Company’s portfolio is comprised of one monoclonal antibody therapy targeting inflammatory disease and two small molecule inhibitors targeting oncology. The Company’s products include ASLAN004, ASLAN003 and Varlitinib. ASLAN004 is a fully human monoclonal antibody that binds to the IL-13 receptor alpha1 subunit (IL-13Rα1), blocking signaling of two pro-inflammatory cytokines, IL-4 and IL-13, which are central to triggering symptoms of atopic dermatitis, such as redness and itching of the skin. ASLAN003 is an inhibitor of human dihydroorotate dehydrogenase (DHODH), in acute myeloid leukemia (AML) and are exploring development in other solid tumors. Varlitinib is an oral, reversible small-molecule pan-HER inhibitor.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Closing Price
Day's Change
0.00 (0.00%)
B/A Size
Day's High
Day's Low

10-day average volume:

UPDATE: Apple stock rockets to record as 'amazingly strong' earnings calm pandemic iPhone fears

11:43 am ET August 1, 2020 (MarketWatch)

By Emily Bary

While new iPhone will be delayed into next fiscal year, sales appear strong enough for older models to weather COVID-19

As Apple Inc. heads toward the anticipated launch of its first 5G-enabled phone later this year, the company just gave a confident signal that its hardware is still very much in demand during a global pandemic.

Apple shares (AAPL) powered to another record high Friday, with the stock crossing the $400 mark for the first time and eventually gaining 10.5% as analysts cheered the company's "amazingly strong" earnings results. The smartphone giant easily weathered the pandemic in its June quarter, according to a Thursday announcement, delivering revenue of $59.7 billion that came in comfortably above estimates even from earlier this year, before analysts slashed their forecasts to account for closed stores, weaker budgets, and other impacts from COVID-19.

See more: Apple beats on earnings and announces stock split, sending shares toward record high (

"Apple's results were amazingly strong and when one considers the COVID-19 pandemic it's even more impressive," wrote Citi analyst Jim Suva, who reiterated a buy rating on the stock and boosted his price target to $450 from $400.

Piper Sandler analyst Harsh Kumar took a similar view.

"Overall, the pandemic seems to be having a limited impact on Apple," he said in a note to clients. "In fact, one can make the case that the Mac and iPad are actually benefiting nicely due to the work from home and distance learning trends."

Mac revenue rose to $7.1 billion from $5.8 billion, while iPad revenue increased to $6.6 billion from $5 billion.

Kumar keyed in on the company's expectation for a strong back-to-school season this year and upped his price target to $450 from $310 while maintaining an overweight rating on the stock.

RBC Capital Markets analyst Robert Muller wrote that the iPhone SE helped Apple drive a new high for its installed base, contributing to smartphone trends that make him "continue to gain confidence behind Apple's ability to drive recurring cash flows from its loyal customer base."

Muller is optimistic about smartphone trends over the next few quarters even as Apple confirmed that its next phone will be delayed by "a few weeks" ( compared with last year, when it began selling its new models toward the end of September. That will push the next iPhone release into Apple's next fiscal year, which begins in October.

"Recall that iPhone X, a highly anticipated form factor upgrade, was released in early November and drove a still-record quarterly iPhone revenue result," he wrote. "Despite anticipation of a 5G upgrade, Apple expects recent iPhone performance (which topped expectations) will continue through next quarter."

He rates the stock at outperform while raising his price target to $445 from $390.

Read: Pandemic? Antitrust? No worries for Big Tech, which racked up $200 billion in sales anyway (

J.P. Morgan's Samik Chatterjee wrote that Apple "surprised even bullish expectations heading into F3Q/C2Q earnings by hardly missing a beat," and he was upbeat about management's tone in looking at the current quarter.

"All in all, Apple's ability as a company in a consumer discretionary product segment to completely buck sequential slowdown in F3Q/C2Q despite the massive disruption speaks volumes to the utility associated by consumers to the products as well as the momentum of a product cycle, which is leading them to be willing to circumvent the traditional practice of buying from the physical channel when required, and leads us to be more optimistic relative to the upcoming 5G product cycle," wrote Chatterjee, who has an overweight rating on the stock and who bumped his price target up to $460 from $425.

Chatterjee said that Apple also has an "underappreciated enterprise opportunity" as more people use Macs and iPads for remote work.

"While the strength in the quarter was expected, led by management's guidance on the last earnings call, the guidance for unit growth trends to sustain into F4Q are likely to surprise investors given that most were likely expecting it to be a one-time tailwind for these products," he wrote.

Canaccord Genuity's T. Michael Walkley also was encouraged that the company expects double-digit growth for all hardware categories except the iPhone in the September quarter, and he praised the "blowout" results for the June period while boosting his price target to $460 from $440 and keeping a buy rating on the stock.

See also: U.S. economy plunges at titanic 32.9% rate in second quarter and points to drawn-out recovery (

At least 19 analysts raised their price targets on Apple's stock following the report, according to FactSet, and the new average target stands at $397.65. Of the 38 analysts tracked by FactSet who cover Apple's stock, 26 rate it a buy, eight rate it a hold, and four rate it a sell.

Apple plans to do a four-for-one split of its stock (, which will impact shareholders of record as of Aug. 24. The stock will start trading on a split-adjusted basis on Aug. 31, a move Citi's Suva said "is important for retail investors." Apple said that the stock split is intended to make the stock "more accessible to a broader base of investors."

Shares are up 39% over the past three months as the Dow Jones Industrial Average has risen 8%.

-Emily Bary; 415-439-6400;

(END) Dow Jones Newswires

August 01, 2020 11:43 ET (15:43 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.